Table 1.

Breast cancer patient characteristics by use of nipple-sparing and non-nipple-sparing unilateral mastectomy in California, 1998–2013

Variable	Unilateral mastectomy, non-nipple-sparing		Unilateral mastectomy, nipple-sparing		Total
	N	Column %	N	Column %
All patients	156,599		993		157,592
Race/ethnicity
Non-hispanic white	103,002	65.8	634	63.8	103,636
Non-hispanic black	8690	5.5	42	4.2	8732
Hispanic	24,368	15.6	140	14.1	24,508
Chinese	4423	2.8	19	1.9	4442
Japanese	2015	1.3	9	0.9	2024
Filipina	6202	4.0	22	2.2	6224
Other Asian/Pacific Islander	6645	4.2	111	11.2	6756
Non-hispanic American Indian/other/unknown	1254	0.8	16	1.6	1270
Age at diagnosis, years
<40	10,537	6.7	128	12.9	10,665
40–49	30,174	19.3	327	32.9	30,501
50–64	52,090	33.3	382	38.5	52,472
65+	63,798	40.7	156	15.7	63,954
Marital status at diagnosis
Not married	64,741	41.3	340	34.2	65,081
Married	88,040	56.2	626	63.0	88,666
Unknown	3818	2.4	27	2.7	3845
Neighborhood SES statewide quintilea
Quintile (Q) 1 (lowest)	21,610	13.8	74	7.5	21,684
Q2	29,697	19.0	127	12.8	29,824
Q3	33,092	21.1	156	15.7	33,248
Q4	35,417	22.6	235	23.7	35,652
Q5 (highest)	36,783	23.5	401	40.4	37,184
Insurance status
None	1330	0.8	5	0.5	1335
Private only	65,849	42.0	621	62.5	66,470
Medicare only/Medicare and private	14,325	9.1	44	4.4	14,369
Any public/Medicaid/military	30,338	19.4	174	17.5	30,512
Unknown	44,757	28.6	149	15.0	44,906
American joint committee on cancer stage
0	11,791	7.5	216	21.8	12,007
I	50,767	32.4	374	37.7	51,141
II	73,696	47.1	336	33.8	74,032
III	20,345	13.0	67	6.7	20,412
Tumor size, cm
<1	18,206	11.6	197	19.8	18,403
1.0–1.9	46,494	29.7	311	31.3	46,805
2.0–2.9	37,838	24.2	211	21.2	38,049
3.0–4.9	33,361	21.3	170	17.1	33,531
5.0+	20,700	13.2	104	10.5	20,804
Grade
I	19,675	12.6	149	15.0	19,824
II	55,522	35.5	396	39.9	55,918
III	56,995	36.4	345	34.7	57,340
Unknown	24,407	15.6	103	10.4	24,510
Histology
Ductal	132,954	84.9	845	85.1	133,799
Lobular or with lobular component	14,125	9.0	92	9.3	14,217
Other	9520	6.1	56	5.6	9576
ER/PR status
Negative (ER and PR both negative)	23,927	15.3	126	12.7	24,053
Positive (ER and/or PR-positive)	92,327	59.0	715	72.0	93,042
Unknown/borderline	40,345	25.8	152	15.3	40,497
Lymph node involvement
Negative	91,755	58.6	735	74.0	92,490
Positive	63,369	40.5	238	24.0	63,607
Unknown	1475	0.9	20	2.0	1495
Received care at NCI-designated cancer center
No	150,310	96.0	906	91.2	151,216
Yes	6289	4.0	87	8.8	6376
Patient SES quintile distributiona of reporting hospital
>=50 % of patients in quintiles 4 or 5 (highest) and <50 % in quintiles 1 or 2	70,021	44.7	672	67.7	70,693
>=50 % of patients in quintiles 1 (lowest) or 2 and <50 % in quintiles 4 or 5	35,404	22.6	129	13.0	35,533
Mixed SES distribution	51,174	32.7	192	19.3	51,366
Received adjuvant treatment (chemotherapy and/or radiation)
No	91,774	58.6	547	55.1	92,321
Yes	64,825	41.4	446	44.9	65,271
Vital status at the end of the study period
Alive	93,815	59.9	875	88.1	94,690
Died of breast cancer	25,948	16.6	37	3.7	25,985
Died of another cause	36,836	23.5	81	8.2	36,917
Variable	Unilateral mastectomy, non-nipple-sparing		Unilateral mastectomy, nipple-sparing		Total
	N	Row %	N	Row %
Year of diagnosis
1988	5924	99.8	14	0.2	5938
2013	5114	94.9	276	5.1	5390

ER, estrogen receptor; NCI, National Cancer Institute; PR, progesterone receptor; SES, socioeconomic status

^aDistribution based on statewide quintiles